Coherus Biosciences Inc (OQ:CHRS)

Apr 24, 2024 10:02 am ET
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4,...
Apr 08, 2024 08:30 am ET
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data...
Mar 13, 2024 04:01 pm ET
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and recent business highlights:  RECENT BUSINESS HIGHLIGHTS   CORPORATE RESTRUCTURING...
Mar 05, 2024 04:01 pm ET
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’...
Mar 04, 2024 01:00 am ET
Coherus Completes Divestiture of Ophthalmology Franchise
Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz,...
Feb 23, 2024 05:33 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the...
Feb 21, 2024 08:30 am ET
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), is successfully underway, with a broad distribution of accounts...
Feb 05, 2024 08:00 am ET
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement entered in January 2022. Following the closing of the previously announced...
Jan 22, 2024 01:15 am ET
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement to divest its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for...
Jan 19, 2024 08:31 am ET
Thinking about buying stock in YanGuFang International, Broadcom, Applied Digital, Intelligent Bio Solutions, or Coherus Biosciences?
NEW YORK, Jan. 19, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YGF, AVGO, APLD, INBS, and CHRS.
Jan 18, 2024 04:05 pm ET
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab...
Jan 04, 2024 07:00 am ET
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
-  Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Jan 03, 2024 09:00 am ET
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time. The presentation and...
Jan 02, 2024 08:29 am ET
Coherus Announces U.S. Launch of LOQTORZI™
Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that LOQTORZI™ (toripalimab-tpzi) is now available through select specialty distributors in the United States. LOQTORZI is indicated in combination with cisplatin and gemcitabine...
Dec 28, 2023 08:31 am ET
Thinking about buying stock in Riot Platforms, Coherus Biosciences, AC Immune, Wisekey International Holding, or NXU Inc.?
NEW YORK, Dec. 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIOT, CHRS, ACIU, WKEY, and NXU.
Dec 27, 2023 08:31 am ET
Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences?
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CING, GRCL, LLY, EPIX, and CHRS.
Dec 26, 2023 04:01 pm ET
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer, today announced that the U.S. Food and Drug...
Dec 22, 2023 05:00 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the...
Dec 11, 2023 08:30 am ET
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) announced today that the National Comprehensive Cancer Network (NCCN) has updated the clinical practice guidelines for nasopharyngeal carcinoma (NPC) to include LOQTORZI™ (toripalimab-tpzi) as a...
Dec 07, 2023 05:55 pm ET
Coherus BioSciences Announces CFO Transition Plans
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pursue other opportunities. Mr. Stilwell’s last day of employment with Coherus will...
Dec 06, 2023 04:00 am ET
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the ongoing Phase 1b/2 clinical trial of casdozokitug (casdozo), a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress...
Nov 28, 2023 11:16 am ET
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Ca
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180) announced today the publication of the final overall survival (OS) results from the pivotal JUPITER-02 study...
Nov 17, 2023 08:31 am ET
Thinking about buying stock in Coinbase Global, Celsius Holdings, Cadence Design Systems, Coherus Biosciences, or Fortress Biotech?
NEW YORK, Nov. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COIN, CELH, CDNS, CHRS, and FBIO.
Nov 07, 2023 08:31 am ET
Thinking about buying stock in Applied Therapeutics, Coherus Biosciences, Tempest Therapeutics, Bluegreen Vacations Holding, or Adams Resources & Energy?
NEW YORK, Nov. 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLT, CHRS, TPST, BVH, and AE.
Nov 06, 2023 04:07 pm ET
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights: RECENT BUSINESS HIGHLIGHTS CIMERLI® CIMERLI® (ranibizumab-eqrn) net product...
Nov 03, 2023 08:30 am ET
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA....
Nov 02, 2023 08:00 pm ET
Coherus BioSciences to Participate at Upcoming November Investor Conferences
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Truist Securities BioPharma Symposium In New York City on Wednesday, November 8, 2023, for 1x1...
Nov 01, 2023 09:31 am ET
Thinking about buying stock in AERWINS Technologies, Arista Networks, Lucid Group, C3.ai, or Coherus Biosciences?
NEW YORK, Nov. 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AWIN, ANET, LCID, AI, and CHRS.
Oct 30, 2023 06:00 pm ET
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management...
Oct 30, 2023 09:31 am ET
Thinking about buying stock in Coherus Biosciences, Vyne Therapeutics, Intuitive Machines, SoFi Technologies, or Cybin?
NEW YORK, Oct. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHRS, VYNE, LUNR, SOFI, and CYBN.
Oct 27, 2023 03:07 pm ET
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), and  Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI™ (toripalimab-tpzi) in...
Oct 24, 2023 07:41 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,500 shares of the...
Oct 14, 2023 12:30 pm ET
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes...
Oct 05, 2023 08:30 am ET
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the Company has resubmitted the Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™, the company's on-body injector presentation of UDENYCA® (pegfilgrastim-cbqv), to...
Oct 04, 2023 08:30 am ET
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that sales of CIMERLI® (ranibizumab-eqrn) to retinal specialists have exceeded 100,000 doses since commercial launch on October 3, 2022. CIMERLI® is the first and only FDA-approved...
Oct 02, 2023 09:00 am ET
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer, today announced recognition and support for...
Sep 27, 2023 09:10 am ET
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention...
Sep 25, 2023 08:30 am ET
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Comp
Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer, announced today that the U.S. Food and Drug...
Sep 22, 2023 09:00 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 109,000 shares of...
Sep 08, 2023 09:05 am ET
Coherus Completes Surface Oncology Acquisition
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc. (Surface or Surface Oncology), a clinical-stage immuno-oncology (I-O) company developing next-generation...
Sep 01, 2023 04:01 pm ET
Coherus BioSciences to Participate at Upcoming September Investor Conferences
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference in Boston on Wednesday, September 6, 2023, including...
Aug 31, 2023 04:01 pm ET
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services (“ISS”) and...
Aug 22, 2023 05:35 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 77,000 shares of the...
Aug 02, 2023 04:01 pm ET
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2023, and recent business highlights: RECENT BUSINESS HIGHLIGHTS CIMERLI® CIMERLI® (ranibizumab-eqrn) net product sales more...
Jul 26, 2023 04:05 pm ET
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus’ management team...
Jul 21, 2023 05:30 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 187,000 shares of the...
Jul 20, 2023 04:04 pm ET
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience...
Jul 13, 2023 08:30 am ET
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a national distribution agreement for YUSIMRY™ (adalimumab-aqvh) at a price of $995 per carton of two...
Jul 03, 2023 08:30 am ET
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors, representing a...
Jun 26, 2023 09:08 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 48,000 shares of the...
Jun 16, 2023 07:01 am ET
Coherus to Acquire Surface Oncology
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface...
Jun 16, 2023 07:01 am ET
Coherus to Acquire Surface Oncology
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface...
Jun 05, 2023 05:30 pm ET
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting. JUPITER-02 is a randomized,...
Jun 01, 2023 08:33 am ET
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced plans to offer Mark Cuban Cost Plus Drug Company customers YUSIMRY...
Jun 01, 2023 08:30 am ET
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date...
May 22, 2023 08:30 am ET
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States. UDENYCA® is a...
May 16, 2023 06:50 am ET
Coherus Prices Public Offering of Common Stock
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share. All of the shares of the common stock to be...
May 15, 2023 04:01 pm ET
Coherus Announces Proposed Public Offering of Common Stock
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to...
May 08, 2023 04:05 pm ET
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
Coherus BioSciences, Inc. (“Coherus”, “the Company”, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2023 and recent business highlights: RECENT BUSINESS HIGHLIGHTS CIMERLI® On April 1st, the permanent,...
May 04, 2023 04:30 pm ET
Coherus BioSciences to Present at Upcoming Investor Conferences in May
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Bank of America Merrill Lynch Global Healthcare 2023 Conference in Las Vegas on Thursday, May 11,...
May 01, 2023 04:07 pm ET
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus’ management team will host a...
Apr 27, 2023 08:05 am ET
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data presentations of four toripalimab pivotal clinical studies will be presented at...
Mar 06, 2023 04:01 pm ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS The U.S. Food...
Mar 06, 2023 08:00 am ET
FDA Approves UDENYCA® Autoinjector
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) approved a single-dose, prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv), a biosimilar pegfilgrastim...
Mar 01, 2023 08:25 am ET
Coherus BioSciences to Present at Upcoming Investor Conferences in March
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7th at 2:10 p.m. ETBarclays 2023...
Feb 28, 2023 08:25 am ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus’...
Feb 15, 2023 08:25 am ET
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal C
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study...
Feb 13, 2023 08:25 am ET
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (HCPCS)...
Feb 03, 2023 05:30 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares of the...
Jan 09, 2023 08:20 am ET
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights to FYB203, a biosimilar...
Jan 04, 2023 07:01 am ET
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentation and Q&A...
Dec 25, 2022 08:16 am ET
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the companies have not received an action letter from the U.S. Food and Drug...
Dec 24, 2022 12:01 am ET
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the companies have not received an action letter from the U.S. Food and Drug...
Dec 23, 2022 07:53 am ET
Thinking about buying stock in ReShape Lifesciences, Exicure, Blue Apron, Coherus Biosciences, or Icecure Medical?
NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RSLS, XCUR, APRN, CHRS, and ICCM.
Nov 08, 2022 04:01 pm ET
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS CIMERLI™...
Nov 01, 2022 07:30 am ET
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022. Starting at 5:00 p.m. Eastern Time on November 8, 2022, Coherus’...
Oct 12, 2022 07:30 am ET
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced...
Sep 19, 2022 07:30 am ET
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) today announced the commercial availability, beginning October 3, 2022, of CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab...
Sep 12, 2022 08:30 am ET
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET. An audio webcast of the...
Aug 29, 2022 08:49 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares of the...
Aug 04, 2022 04:01 pm ET
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS The U.S. Food and Drug Administration (FDA) has...
Aug 02, 2022 07:15 pm ET
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab...
Aug 01, 2022 11:15 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the...
Jul 28, 2022 04:01 pm ET
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022. Starting at 5 p.m. ET, Coherus’ management team will host a...
Jul 06, 2022 08:00 am ET
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the...
Jun 22, 2022 04:30 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the...
May 11, 2022 06:00 pm ET
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of cancer immunotherapy leader Jill O’Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O’Donnell-Tormey will also serve on the Nominating and Corporate...
May 10, 2022 08:45 am ET
Coherus BioSciences Management to Present at Upcoming Investor Conferences
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ETUBS Global...
May 05, 2022 04:01 pm ET
Coherus BioSciences Reports First Quarter 2022 Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2022 and recent business highlights: RECENT BUSINESS HIGHLIGHTS After receiving a complete response letter...
May 05, 2022 08:31 am ET
Coherus BioSciences Appoints Charlie Newton to Board of Directors
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors. Mr. Newton will also serve on the Audit...
May 03, 2022 09:44 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 27, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of the...
May 02, 2022 07:00 am ET
Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, “Junshi”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (“FDA”, “the Agency”) has issued a...
Apr 29, 2022 04:01 pm ET
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET, not 5 p.m. ET as previously stated. The corrected release...
Apr 29, 2022 08:45 am ET
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022. Starting at 4:30 p.m. ET,...
Apr 14, 2022 08:30 am ET
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug...
Apr 08, 2022 01:10 pm ET
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the results of the prespecified final progression-free survival (“PFS”) analysis and the interim...
Apr 05, 2022 04:30 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 31, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares of the...
Mar 29, 2022 09:15 am ET
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), beginning at 9:30 a.m. Eastern Daylight Time today, is hosting a meeting with analysts and investors to present the Company’s corporate strategy to build a leading innovative immuno-oncology...
Mar 22, 2022 04:30 pm ET
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City. Coherus executives and scientists will provide updates on the preparation for...
Mar 15, 2022 08:00 am ET
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer. Dr. Dias will serve as a member of the Company's executive leadership team and oversee a number of...
Mar 15, 2022 07:30 am ET
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for No
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the presentation of positive results and biomarker analyses from the pivotal study...
Mar 04, 2022 04:05 pm ET
Coherus Management to Present at Upcoming Investor Conferences
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March. 42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m. ETBarclays Global...
Mar 04, 2022 08:00 am ET
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the online publication in Cancer Cell of Toripalimab plus chemotherapy in treatment-naïve,...
Feb 17, 2022 04:01 pm ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter and full year ended December 31, 2021 and highlighted recent achievement of important milestones toward the Company’s key...
Feb 15, 2022 04:30 pm ET
Coherus Names Paul Reider Chief Commercial Officer
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Operations and Market...
Feb 14, 2022 08:30 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Feb. 9, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 236,500 shares of the...
Feb 11, 2022 08:30 am ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m. ET, Coherus’ management team...
Feb 07, 2022 08:30 am ET
Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N. Newcomer, M.D., to its Board of Directors effective February 2, 2022. “We...
Jan 10, 2022 07:30 am ET
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that Coherus has initiated the process to exercise its option to license JS006, Junshi...
Jan 07, 2022 08:30 am ET
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors
Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP. “As Coherus enters a period of projected significant topline...
Jan 04, 2022 08:32 am ET
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST. The audio portion of the...
Jan 04, 2022 08:30 am ET
Coherus BioSciences’ Management to Present at the 40th Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST. The audio portion of the...
Dec 20, 2021 08:31 am ET
Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus Biosciences, ImmunityBio, or SeaChange International?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, SELB, CHRS, IBRX, and SEAC.
Dec 20, 2021 07:59 am ET
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”)...
Dec 17, 2021 09:09 am ET
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer
Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Company’s executive leadership team and oversee all regulatory matters...
Dec 16, 2021 04:30 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Dec. 13, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 367,000 shares of the...
Dec 13, 2021 07:00 am ET
Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of overall survival from the pivotal study...
Dec 13, 2021 07:00 am ET
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive results of an interim analysis of overall survival from the pivotal study...
Nov 15, 2021 08:30 am ET
Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug...
Nov 15, 2021 08:30 am ET
Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug...
Nov 10, 2021 04:15 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Nov. 5, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 177,500 shares of the...
Nov 08, 2021 04:01 pm ET
Coherus BioSciences Reports Third Quarter 2021 Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2021 and highlighted recent achievement of key milestones toward potential near-term expansion of the...
Nov 05, 2021 08:30 am ET
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022...
Nov 01, 2021 07:30 am ET
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the...
Nov 01, 2021 07:30 am ET
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the...
Oct 29, 2021 04:11 pm ET
Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus’ management team will host a...
Oct 11, 2021 08:30 am ET
Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson
It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal...
Oct 05, 2021 08:00 am ET
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
Coherus BioSciences, Inc. (“the Company”; Nasdaq: CHRS) today announced positive results from a randomized, open-label, crossover study assessing the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of UDENYCA® (pegfilgrastim-cbqv)...
Oct 04, 2021 08:00 am ET
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular De
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that positive results from the pivotal COLUMBUS-AMD clinical trial evaluating and comparing the efficacy and safety between CHS-201 and Lucentis® (ranibizumab) in the treatment of...
Oct 01, 2021 01:09 pm ET
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the United States Food and Drug Administration (FDA) has accepted for review the 351(k) Biologics License Application (BLA) for CHS-201, a biosimilar candidate of reference product...
Sep 29, 2021 04:30 pm ET
Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum
It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare...
Sep 24, 2021 04:15 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Sept. 22, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 229,500 shares of the...
Sep 16, 2021 06:28 pm ET
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemother
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced positive interim results from the pivotal study “JUPITER-06” (NCT03829969), a randomized,...
Sep 15, 2021 08:30 am ET
Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced publication of a cover article in the September issue of Nature Medicine featuring clinical...
Sep 13, 2021 08:55 pm ET
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Nasdaq: CHRS) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a...
Sep 13, 2021 08:35 pm ET
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a...
Sep 10, 2021 08:45 am ET
Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET on Tuesday, September 14,...
Sep 08, 2021 08:30 am ET
Coherus BioSciences Announces Upcoming Medical Conference Presentations
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at the...
Sep 01, 2021 08:01 am ET
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of the Biologics License Application (“BLA”) to...
Aug 27, 2021 04:15 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Aug. 26, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 278,000 shares of the...
Aug 19, 2021 08:30 am ET
Thinking about buying stock in Coherus Biosciences, Macy's, Salarius Pharmaceuticals, Verb Technology, or Senseonics?
NEW YORK, Aug. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHRS, M, SLRX, VERB, and SENS.
Aug 18, 2021 09:09 pm ET
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Ce
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized,...
Aug 18, 2021 06:41 pm ET
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Ce
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized,...
Aug 12, 2021 08:01 am ET
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the United States Food and Drug Administration (“FDA”) has recently granted...
Aug 12, 2021 08:01 am ET
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the United States Food and Drug Administration (“FDA”) has recently granted...
Aug 05, 2021 04:01 pm ET
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2021. The Company also provided a progress update on its PD-1 blocking antibody, toripalimab, its lead...
Jul 26, 2021 04:31 pm ET
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus’ management team will host a...
Jul 21, 2021 09:15 am ET
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB). With Dr....
Jul 12, 2021 08:29 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of the...
Jun 04, 2021 04:01 pm ET
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the companies will host a virtual investor event on Monday, June 7, 2021 at 6 p.m....
Jun 03, 2021 08:45 pm ET
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyn
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results from the pivotal study “JUPITER-02”, a randomized, double-blind,...
Jun 03, 2021 05:00 pm ET
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyn
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results from the pivotal study “JUPITER-02”, a randomized, double-blind,...
May 07, 2021 04:01 pm ET
Coherus BioSciences to Present at the Bank of America Health Care Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST. The audio portion of the...
May 06, 2021 04:01 pm ET
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2021. The Company also provided a progress update on its anti-PD-1 antibody, toripalimab, its lead...
Apr 30, 2021 04:15 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 28, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 483,000 shares of the...
Apr 30, 2021 08:15 am ET
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET, Coherus’ management team...
Apr 29, 2021 07:30 am ET
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab,...
Apr 29, 2021 07:30 am ET
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab,...
Apr 23, 2021 08:00 am ET
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinom
Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal...
Apr 20, 2021 08:00 am ET
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences. Under the terms of the February 2, 2021 stock purchase agreement, Coherus has received $50 million from...
Mar 03, 2021 06:45 am ET
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the initiation of the rolling submission of the Biologics License Application (“BLA”) for...
Mar 03, 2021 06:45 am ET
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the initiation of the rolling submission of the Biologics License Application (“BLA”) for...
Feb 25, 2021 08:45 am ET
Coherus Management to Present at Upcoming Investor Conferences
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. 41st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m. ETBarclays Global...
Feb 24, 2021 04:01 pm ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed recent corporate events and reported financial results for the quarter and full year ended December 31, 2020. UDENYCA® (pegfilgrastim-cbqv) delivered strong...
Feb 18, 2021 08:30 am ET
Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news release will be...
Feb 17, 2021 07:30 am ET
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira® (adalimumab)...
Feb 16, 2021 08:00 am ET
Coherus Announces CFO Transition Plans
Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity. McDavid Stilwell has been...
Feb 02, 2021 08:30 am ET
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic...
Feb 01, 2021 07:53 am ET
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc....
Feb 01, 2021 05:30 am ET
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced a collaboration with Shanghai Junshi Biosciences, Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) for the development and commercialization of toripalimab, Junshi...
Jan 22, 2021 04:01 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares of the...
Jan 07, 2021 04:01 pm ET
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021.  “We are excited to welcome Alan and Mark to the Coherus Board of...
Jan 05, 2021 04:01 pm ET
Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST. The audio portion...
Dec 21, 2020 04:02 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 66,000 shares of the...
Nov 20, 2020 04:01 pm ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 140,500 shares of the...
Nov 05, 2020 04:02 pm ET
Coherus BioSciences Reports Third Quarter 2020 Financial Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the third quarter and nine months ended September 30, 2020. “In September, Coherus celebrated its ten year...
Oct 22, 2020 04:15 pm ET
Coherus BioSciences to Report Third Quarter Financial Results on November 5th
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a...
Oct 16, 2020 09:30 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 15, 2020, the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to buy...
Sep 18, 2020 11:01 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 118,000 shares of...
Aug 21, 2020 09:30 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,000 shares of the...
Aug 06, 2020 04:02 pm ET
Coherus BioSciences Reports Second Quarter 2020 Financial Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter ended June 30, 2020. Second Quarter 2020 and Recent Corporate Highlights Net product revenue...
Aug 03, 2020 04:49 pm ET
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020.  “We are very pleased to welcome Kimberly Tzoumakas to our Board during this...
Jul 17, 2020 09:30 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 16, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 53,000 shares of the...
Jul 16, 2020 09:30 am ET
Coherus BioSciences to Report Second Quarter Financial Results on August 6th
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020. Starting at 4:30 p.m. ET, Coherus’ management team will host a...
Jun 19, 2020 09:30 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 93,000 shares of the...
May 26, 2020 06:16 pm ET
Essent Group Set to Join S&P MidCap 400; Coherus BioSciences, Patterson-UTI Energy to Join S&P SmallCap 600
NEW YORK, May 26, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Monday, June 1:
May 07, 2020 04:08 pm ET
Coherus BioSciences Reports First Quarter 2020 Financial Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter ended March 31, 2020. First Quarter 2020 and Recent Corporate Highlights Strong financial...
May 04, 2020 09:30 am ET
Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET. The audio portion of the...
Apr 22, 2020 09:30 am ET
Coherus BioSciences to Report First Quarter Financial Results on May 7th
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020. Starting at 4:30 p.m. ET, Coherus’ management team...
Apr 15, 2020 12:05 am ET
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 (the “notes”) in a private...
Apr 14, 2020 07:52 am ET
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior subordinated notes due 2026 (the...
Apr 13, 2020 09:23 am ET
Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced preliminary unaudited revenue for UDENYCA® and net income for the quarter ended March 31, 2020. Coherus also provided an update on the impact of COVID-19 for...
Mar 20, 2020 09:30 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 57,500 shares of the...
Mar 05, 2020 04:09 pm ET
Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on Tuesday, March 10, 2020 at 8:30 a.m. ET, being held in Miami. The audio portion of the...
Mar 05, 2020 07:00 am ET
United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its United States manufacturing and distribution is well positioned to ensure uninterrupted availability of UDENYCA® for patients. Coherus does not source active...
Feb 27, 2020 04:01 pm ET
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2019.  Fourth Quarter 2019 and Recent Corporate...
Feb 26, 2020 09:30 am ET
Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. ET, being held in Boston. The audio portion of the...
Feb 20, 2020 11:19 am ET
Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase 135,000 shares of the common stock of...
Feb 06, 2020 09:34 am ET
Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th
Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February 27, 2020. Starting at 4:30 p.m. ET,...
Jan 13, 2020 08:30 am ET
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd., (“Innovent”), a leading biopharmaceutical company headquartered in...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.